<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158144</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH03</org_study_id>
    <nct_id>NCT01158144</nct_id>
  </id_info>
  <brief_title>Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)</brief_title>
  <official_title>A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable,
      non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still
      controversial. The purpose of this study was to evaluate the efficacy and toxicity of a
      concomitant treatment using Endostar (Recombinant Human Endostatin), Paclitaxel/Carboplatin
      and radiotherapy for LA-NSCLC, and also assess its impact on patient Quality of Life (QoL)
      and progression-free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation
      therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours
      d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min
      weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5
      mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response rate</measure>
    <time_frame>1 month after treatment.</time_frame>
    <description>Response was analyzed according to the RECIST system, based on CT scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>baseline to date of death from any cause</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conctrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.</description>
    <arm_group_label>Endostar</arm_group_label>
    <other_name>Recombinant Human Endostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/Carboplatin</intervention_name>
    <description>Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.</description>
    <arm_group_label>Conctrol</arm_group_label>
    <other_name>PC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven non-small cell lung cancer (squamous cell carcinoma,
             adenocarcinoma, large cell carcinoma and etc)

          -  Presence of measurable disease by RECIST

          -  stage IIIA or IIIB, non-resectable

          -  ECOG performance status 0-1

          -  No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy
             .Patients must sign an informed consent indicating that they are aware of the
             .investigational nature of the study in keeping with the policy of the hospital.

        Exclusion Criteria:

          -  Carcinoid tumor, small cell carcinoma of lung

          -  Patients with any distant metastasis

          -  History of another malignancy except cured basal cell carcinoma of skin and cured
             carcinoma in-situ of uterine cervix

          -  Any other morbidity or situation with contraindication for radiotherapy (e.g. active
             infection, myocardial infarction preceding 6 months, symptomatic heart disease
             including unstable angina, congestive heart failure or uncontrolled arrhythmias,
             immunosuppressive treatment)

          -  Pregnant or lactating women, women who has not taken test of pregnancy (within 7 days
             before the first administration) and pregnant women

          -  Women and men of childbearing potential who have no willing of employing adequate
             contraception Tumor EGFR wild
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenglin Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenglin Ma, MD</last_name>
    <phone>+8657188122568</phone>
    <email>mashenglin@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaping Xu, MD</last_name>
    <phone>+8657188122082</phone>
    <email>xuyaping1207@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenglin Ma, MD</last_name>
      <phone>+8657188122568</phone>
      <email>mashenglin@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yaping Xu, MD</last_name>
      <phone>+8657188122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Ya ping, MD</last_name>
      <phone>0086-571-88122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shenglin Ma</name_title>
    <organization>Zhejiang Cancer Hospital</organization>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Concomitant Chemotherapy</keyword>
  <keyword>Endostar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

